Jim Glasheen, Ph.D., President and Chief Business Offer of Clade Therapeutics added, “Gadeta has generated compelling in-vitro and in-vivo data over the last few years with its lead gamma/delta (g/d) TCRs in solid tumor indications and we’re excited to integrate this novel targeting into Clade’s solid tumor programs. This integration seamlessly complements Clade's existing platform and commitment to developing engineerable, off-the-shelf, scalable, and consistent cell medicines.” The acquisition of Gadeta represents a strategic move to integrate a third element to our platform: ‘Universal Targeting’. “Our technology platform consists of both a ‘Cell Foundry’ that enables the generation of adult immune cells including both CD8+ and CD4+ T Cells, as well as a ‘Cloaking Engine’ that ensures best-in-class and tuned protection from both the cellular and humoral wings of a host’s immune system. “Clade is at the forefront of broadening the impact of cell therapy by establishing a more robust cellular platform with stem-cell derived immune cells,” said Chad Cowan, Ph.D., Chief Executive Officer of Clade Therapeutics. Gadeta shareholders will receive upfront and downstream economics. Under the terms of the acquisition agreement, Clade has acquired all outstanding shares of Gadeta, making it a wholly owned subsidiary of Clade. The integration of Gadeta’s g/d TCR targeting technology is complementary to Clade’s cellular platform technology and will enhance the development of engineerable, off-the-shelf, scalable, and consistent stem-cell based medicines. The acquisition will provide Clade with preclinical cell therapy programs, g/d TCR discovery engine and a suite of cell enhancement to improve anti-tumor activity of cell therapies. These g/d TCRs recognize unique patterns or targets on the surface of cancer cells that signal that they are diseased, thereby specifically targeting cancer cells and sparing healthy cells. The company developed a proprietary platform to engineer novel g/d TCRs that possess broad tumor targeting capabilities. Gadeta is an international R&D company, focused on innovative immunotherapies for cancer. (“Gadeta”), a cell therapy company developing innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies for cancer patients. 02, 2023 (GLOBE NEWSWIRE) - Clade Therapeutics (“Clade”), a biopharmaceutical company focused on discovering and delivering engineerable, off-the-shelf, scalable, and consistent stem cell-based medicines, today announced that it has completed the acquisition of Gadeta B.V. g/d TCR candidate integrated into Clade’s solid tumor pipelineīOSTON, Oct. proprietary gamma/delta (g/d) TCR universal targeting platform technology, “We are greatly impressed with the Kite team and what they have accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer.Clade Therapeutics Announces the Acquisition of Gadeta B.V. “The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers,” said Gilead’s President and Chief Executive Officer John F. Industry experts expect the therapy to be the first to market to treat refractory aggressive non-Hodgkin lymphoma. Its CAR-T drug is currently under priority review by the U.S. Kite has been in the race to develop CAR-T therapies with other pharmaceuticals such as Novartis, Juno Therapeutics, and Bluebird bio. Kite Pharma is a leading immunotherapy company, well-known for developing chimeric antigen receptor T-cell (CAR-T) therapy that reengineers a patient’s white blood cells to attack cancer cells. Industry insiders have long expected Gilead, which had recorded having $32 billion in cash assets at the end of 2016, to use its funds to invest in a new area. ■ Related : Gilead’s hepatitis B therapy to vie with 20 Korean therapies However, the hepatitis C market has since seen fierce competition and falling prices that resulted in Gilead experiencing a $ 4 billion reduction in sales this year compared to a year earlier. Gilead had reportedly generated $30.39 billion in sales last year, with 48.7 percent stemming from hep C treatment sales. Gilead has since 2013 relied on its blockbuster hepatitis drugs as the primary source of revenue after acquiring hep C drug developer Pharmasset for $11 billion in 2011. The acquisition signals a significant move for the California-based biotech company that is looking towards cancer immunotherapies as the next big growth engine. Gilead will pay $180 per share for Kite, the company said Monday. Gilead, the developer of blockbuster hepatitis C and HIV treatments, said Monday it has agreed to acquire immunotherapy company Kite Pharma for $11.9 billion later this year, adding a next-generation cancer treatment to its portfolio.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |